Zealand Pharma's CEO Adam Steensberg weighs in on early-stage trials of its obesity drug contender and talks down takeover ...

A CNBC investigation into illegal weight loss drugs reveals a marketplace where criminals brazenly counterfeit the drugs or ...

The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's ...

Therapies that deliver hydrogen sulfide to cells could one day become the basis of new treatments for obesity and related ...

The FDA decision will enable Antag Therapeutics to initiate the clinical development of its lead candidate drug, a ...

Newly released data shows that the U.S. may have reached peak obesity in 2020 — and the timing unsurprisingly coincides with ...

New-generation anti-obesity drug Wegovy, made by the same company that created Ozempic, is now available in France – but it ...

The United States has passed peak obesity, according to new data, suggesting that the sweeping uptake of weight-loss drugs ...

Medicare is prohibited by law from covering GLP-1 drugs for weight loss. But many beneficiaries can access the drugs anyway.

Allowing Medicare to cover anti-obesity medications would drive up federal spending by about $35 billion on net between 2026 and 2034, according to ...

The cost of taking weekly injections of popular anti-obesity medications liraglutide (Saxenda) or semaglutide (Wegovy) ...

Ilant estimates that behavioral therapy can help many people lose up to 5% of their weight, anti-obesity medications can help ...